|
| Study on the clinical efficacy and mechanism of Hashi Zhidai Formulation Ⅱ in treating damp-heat Bacterial Vaginosis |
| Hits 549 Download times 354 Received:March 10, 2022 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1673-9043.2022.04.09 |
| Key Words
bacterial vaginosis;damp-heat bet type;Hashi Zhidai Formulation Ⅱ;vaginal lactobacilli;vaginal local immunity |
| Author Name | Affiliation | E-mail | | CHU Mengyuan | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Rersearch Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China | | | WU Linling | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Rersearch Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China | | | YAN Ying | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Rersearch Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China | yanying799@163.com |
|
| Abstract
|
| [Objective] To explore the clinical efficacy of Hashi Zhidai Formulation Ⅱ in the treatment of bacterial vaginosis(BV), the change in the number of lactobacilli in the vagina, and the local immunity of the vagina.[Methods] The 48 patients with damp invasion of lower energizer BV who met the inclusion and exclusion criteria were selected from the gynecological clinic of the First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine from January 2020 to December 2020. The patients were divided into treatment group (24 cases) and control group(24 cases) through a randomized controlled research method. The control group was treated with tinidazole suppository, and the treatment group was taken orally on the basis of the control group Hashi Zhidai Formulation Ⅱ, and both were treated for 1 course of treatment. Observe the Nugent score, the number of lactobacilli in the vagina before and after treatment, and the concentration of IL-1β, IL-6 and TNF-α in the vagina before and after treatment. Patients with Nugent score less than 7 after treatment were followed up for observation at 1, 2, and 3 months after treatment.[Results] The clinical efficacy of the treatment group was better than that of the control group, and the difference was statistically significant (P < 0.05). The treatment group can increase the number of vaginal lactobacillii in the vagina after treatment and was better than the control group, the difference was statistically significant(P < 0.05). After treatment, the treatment group was better than the control group in reducing the concentration of IL-1β, IL-6 and TNF-α in the vagina, and the difference was statistically significant(P < 0.05). Follow-up for the first 1, 2, and 3 months after the treatment, the Nugent scores of the two groups after treatment decreased compared with that before treatment, and the difference was statistically significant(P < 0.05), and the treatment group had a greater downward trend. The treatment group's Nugent scores of the first, second, and third months were lower than those of the control group after treatment, and the differences were statistically significant (P < 0.05). In the first month after treatment, the treatment group increased the number of vaginal lactobacilli better than the control group, and the difference was statistically significant (P < 0.05). In the first month after treatment, the treatment group increased the number of vaginal lactobacilli better than the control group, and the difference was statistically significant (P < 0.05).[Conclusion] Hashi Zhidai Formulation Ⅱcan treat damp-heat betting type BV, increase the number of vaginal lactobacilli in the vagina, reduce the concentration of IL-1β, IL-6, and TNF-α in the vagina and prevent recurrence. |
|
|
|
|
|
